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Background: The quadrivalent human papillomavirus (qHPV) vaccine prevented vaccine HPV type-related infec-
tion and disease in young women in the 4-year FUTURE II efficacy study (NCT00092534). We report long-term
effectiveness and immunogenicity at the end of 14 years of follow-up after enrollment in FUTURE II.
Methods: Young women (1623 years of age) from Denmark, Iceland, Norway, and Sweden who received
three qHPV vaccine doses during the randomized, double-blind, placebo-controlled FUTURE II base study
were followed for effectiveness for an additional 10 years through national registries. Tissue samples
including but not limited to those collected during organized cervical cancer screening programs were
obtained from regional biobanks to be adjudicated for histopathology diagnosis and tested for HPV DNA. The
observed incidence of HPV16/18-related high-grade cervical dysplasia (primary outcome) was compared
with recent historical background incidence rates in an unvaccinated population. Serum was collected at
years 9 and 14 to assess antibody responses.
Findings: No cases of HPV16/18-related high-grade cervical dysplasia were observed in the per-protocol
effectiveness population (N = 2121; 24,099¢0 person-years of follow-up) during the entire study. Vaccine
effectiveness of 100% (95% CI 94¢7100) was demonstrated for 12 years, with a trend toward continued
protection through 14 years post-vaccination. Seropositivity rates at study conclusion were >90% (HPV6/11/16)
and 52% (HPV18) using competitive Luminex immunoassay, and>90% (all four HPV types) using themore sensitive
IgG Luminex immunoassay.
Interpretation: Vaccination of young women with qHPV vaccine offers durable protection against
HPV16/18-related high-grade cervical dysplasia for 12 years, with a trend toward continued protection
through 14 years post-vaccination, and induces sustained HPV6/11/16/18 antibody responses for up to
14 years post-vaccination. There was no evidence of waning immunity, suggesting no need for a booster
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Human papillomavirus (HPV) causes 690,000 new cancer cases
per year worldwide, including nearly all the more than 560,000 cases
of cervical cancers that occur globally each year (based on 2018 esti-
mates) [1], as well as a significant proportion of vulvar, vaginal, anal,
penile, and oropharyngeal cancers [1,2]. Indeed, approximately 4.5%
of all cancers (8.6% in women) are attributable to HPV [2]. The quadri-
valent HPV (qHPV) vaccine was developed to protect against HPV
types 16 and 18, which are responsible for approximately 70% of cer-
vical cancers and most cases of HPV-related vulvar, vaginal, and anal
cancers based on epidemiological studies [25], as well as HPV6 and
11 which cause approximately 90% of genital warts [6]. In clinical tri-
als, the qHPV vaccine prevented HPV6/11/16/18-related cervical and
anogenital dysplasia and genital warts, and elicited robust antibody
responses [7,8]; the vaccine was initially licensed in 2006 and is now
widely used in national immunization programs [9]. Post-licensure
studies conducted in the decade following initial approval of qHPV
vaccine have supported the favorable effectiveness and safety profile
observed in the clinical program [10,11].
The average length of follow-up in the pivotal efficacy studies,
Females United to Unilaterally Reduce Endo/Ectocervical Disease(FUTURE) I and II, was approximately 4 years [12,13]. The qHPV vac-
cine demonstrated efficacy against HPV16/18-related cervical intrae-
pithelial neoplasia (CIN) grade 2 or 3 and adenocarcinoma in situ
(AIS) in the FUTURE II base study in more than 12,000 young women
globally [13,14]. As the risk for HPV exposure can be lifelong [15],
protective efficacy of the vaccine lasting decades is required to
achieve the full benefit of vaccination. Ten additional years’ extension
of the follow-up time of the FUTURE II base study in Nordic countries
was feasible and a long-term follow-up (LTFU) study was imple-
mented to assess effectiveness and immunogenicity of the qHPV vac-
cine after completion of the base study; ie, up to 14 years post-
vaccination. This extension was a post-licensure requirement from
the United States Food and Drug Administration and the European
Medicines Agency [16,17]. The final qHPV vaccine effectiveness and
immunogenicity results of the LTFU study through 14 years post-vac-
cination are reported here.2. Methods
2.1. Study design and participants
In the double-blind base study (FUTURE II; NCT00092534),
12,167 participants were enrolled at 90 sites in 13 countries [14].
Base-study participants were assessed for efficacy, immunogenic-
ity, and safety for approximately 4 years in the base study, and
the results have been reported [13,14,18].
The LTFU study is an extension of the base study among study par-
ticipants from the Nordic countries of Denmark, Iceland, Norway, and
Sweden. Participants from these countries were 16 to 23 years of age
at the start of the base study. These countries have established orga-
nized cervical cancer screening programs with routine centralized
administration and registration, with close to 100% completeness
and accuracy [1925]. During the base study, participants were not
screened in the national programs (since they were screened within
the study); they resumed participation in the national programs after
the end of the base study. The LTFU study used registry-based follow-
up to assess effectiveness and active follow-up with serum collection
to assess immunogenicity.
Nordic participants who agreed to long-term passive registry
follow-up, re-analysis of biopsy specimens, future contact with
LTFU study investigators, and/or serum collection for the LTFU
study by providing written consent (as needed per local require-
ments) were eligible for the LTFU study. The LTFU study was con-
ducted in accordance with principles of Good Clinical Practice,
and was approved by the appropriate scientific ethics committees
and regulatory agencies.2.2. Randomization and masking
The base-study participants were equally randomized to receive
three doses of qHPV vaccine or placebo, administered intramuscu-
larly at day 1, month 2, and month 6. Randomization and masking
procedures for the base study have been described in detail previ-
ously [14]. Vaccination assignments were unblinded at the end of the
base study, and placebo recipients were offered qHPV vaccination.
In this report, we present follow-up results of the base-study par-
ticipants who were randomized to receive qHPV vaccine at the start
of the base study; no vaccinations were administered during the
LTFU study.
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A National Registry Study Center (NRSC) was established in each
of the four Nordic countries to obtain nation-wide registry-based fol-
low-up data, access biological specimens, and manage blood collec-
tions. At enrollment in the base study, participants received a unique
allocation number (AN). Each resident in Nordic countries also has a
unique personal identification number (PIN), which is used univer-
sally in the society of the individual countries. The NRSCs established
a link between the AN and PIN to obtain study participant informa-
tion from the relevant data stored in the national registries.
For long-term effectiveness, LTFU-study participants were fol-
lowed through linkages with national cancer registries and organized
screening programs for cervical, vulvar, and vaginal abnormalities.
The NRSCs conducted retrospective searches of the national registries
to acquire data for effectiveness evaluation, including cervical cancer
screening-related biopsy and treatment specimens and reports;
acquired results from screening and follow-up visits (including cervi-
cal cytology test results, cervical biopsy and cervical surgery results,
and diagnoses of vulvar and vaginal precancers and cancers);
retrieved clinical histological specimens from the clinical biobanks/
archives existing in all Nordic countries (including hematoxylin and
eosin [H&E]-stained slides and formalin fixed paraffin-embedded tis-
sue blocks); and routed specimens to the Nordic Coordinating Center
(NCC). The NCC was responsible for the administrative processes
related to the Pathology Panel and routing tissue blocks and pathol-
ogy reports to the designated central laboratories for processing. The
central laboratories created the histology slides, which were routed
back to the NCC for Pathology Panel circulation and thin-section sam-
ples. These samples were routed to the testing laboratory for poly-
merase chain reaction (PCR) analysis.
For long-term immunogenicity, the participants were requested
to visit a designated blood collection center to provide serum sam-
ples for immunogenicity assessments at years 5 and 10 of the LTFU
study, corresponding to approximately 9 and 14 years (or 108 and
168 months) of total follow-up post-vaccination. These results were
coupled with the serum samples collected at months 7, 24, and 48 for
immunogenicity assessment in the base study.
2.4. Outcomes
The primary outcome of the LTFU study was the combined inci-
dence of CIN grade 2 or 3 (CIN2, CIN3), AIS, and cervical cancer
(referred to as CIN2 or worse) related to HPV16 and 18. Secondary
outcomes included (1) the combined incidence of HPV6/11/16/18-
related CIN (any grade), AIS, and cervical, vulvar, and/or vaginal can-
cer; (2) the combined incidence of CIN2 or worse related to 10 non-
vaccine HPV types (HPV31/33/35/39/45/51/52/56/58/59); and (3) the
geometric mean titres (GMTs) and seropositivity rates for HPV6, 11,
16, and 18 at years 5 and 10 of the LTFU study. An exploratory out-
come was the incidence of HPV6/11/16/18-related cervical, vaginal,
and vulvar disease in participants who were previously infected with
these types (ie, baseline HPV DNA PCR negative/seropositive).
A case of the primary outcome related to a given HPV type occurred if
a participant developed a lesion with a consensus diagnosis by the Nor-
dic Pathology Panel of CIN2, CIN3, AIS, or cervical cancer, and PCR testing
detected the relevant HPV type in an adjacent section from the same tis-
sue block, as described previously [26]. If multiple HPV types were
detected, the lesion was classified as related to each of the HPV types
detected. For all efficacy endpoints, HPV DNA detection by PCR was con-
sidered a surrogate marker of HPV infection.
The methodology for PCR testing for 14 HPV types [27,28] and
pathology diagnosis adjudication on thin sections of tissue samples
[14,26] was the same as in the base study, except the composition of
the Nordic Pathology Panel in the LTFU study, which was distinct
from the pathology panel that adjudicated the histology samplesduring the base study (see appendix for details). The base study and
LTFU study used the same validation and adjudication processes to
ensure consistency throughout the entire duration of the study.
GMTs and seropositivity to HPV types 6, 11, 16, and 18 were mea-
sured using the competitive Luminex immunoassay (cLIA) [2931],
which was also the primary immunoassay in the base study, and the
immunoglobulin G Luminex immunoassay (IgG-LIA) [32]. Results
of the cLIA and IgG-LIA are reported as antibody concentrations
in arbitrary milli-Merck units per milliliter; however, the meas-
urements represent different outputs and the two assays are not
directly comparable.2.5. Statistical analyses
The primary hypothesis was that the qHPV vaccine will remain
90% effective compared with an unvaccinated population for at
least 14 years after the start of vaccination in preventing HPV 16/
18-related CIN2, CIN3, AIS, and cervical cancer (ie, CIN2 or worse).
qHPV vaccine effectiveness was calculated as 100 x (1  relative
risk), where relative risk is the ratio of the incidence of
HPV16/18-related CIN2 or worse observed in participants followed
in the LTFU and the expected incidence in an unvaccinated
Nordic population. The incidence of HPV16/18-related CIN2 or
worse in an unvaccinated Nordic population was estimated as
0¢287/100 person-years based on data from Nordic national regis-
tries and a questionnaire study (the Concomitant Cohort Study
[33]) (see appendix). To demonstrate the hypothesis of vaccine
effectiveness 90%, the incidence rate observed in participants of the
LTFU study should not have exceeded 0¢0287/100 person-years,
which is 10% of the 0¢287/100 person-years incidence in an unvacci-
nated population.
An adapted Poisson Shewhart-based control chart method was used
for the primary analysis of monitoring breakthrough disease and waning
vaccine effectiveness. The use of a control chart method for monitoring
disease incidence was an innovative and unique aspect of this study and
allowed for prospective monitoring and rapid detection of rises in inci-
dence rates. A full description of the methodology can be found in the
appendix. Briefly, incidence of HPV16/18-related CIN2 or worse was
evaluated at 2-year intervals during the LTFU period, starting at approxi-
mately year 4 post-vaccination and plotted in the control chart. If the
plotted incidences at 2-year intervals conformed to a pre-specified pat-
tern of crossing the 2- and 3-sigma upper control limits of the control
chart, an inference would be made that the accumulating data were
indicative of waning effectiveness.
The primary effectiveness analysis was conducted in the per-pro-
tocol effectiveness (PPE) population consisting of participants who
(1) received three doses of qHPV vaccine within 1 year; (2) had no
protocol violations that could impact vaccine effectiveness; (3) were
PCR-negative and seronegative at baseline and PCR-negative through
month 7 of the base study for the appropriate HPV type(s); and (4)
consented to effectiveness follow-up. Some supportive effectiveness
analyses were conducted in the HPV-naïve to relevant type (HNRT)
population of participants who (1) received at least one vaccination;
(2) had any follow-up visit in the LTFU study; and (3) were PCR-nega-
tive and seronegative to the appropriate HPV type(s) prior to vaccina-
tion. In addition, exploratory analyses were conducted in participants
with evidence of prior exposure to HPV at day 1 of the base study.
Immunogenicity was analyzed in the per-protocol immunogenic-
ity (PPI) population, which comprised participants who (1) were
sero- and PCR-negative at baseline and PCR-negative through month
7 of the base study to the appropriate HPV type(s, 2) received three
doses of qHPV vaccine within specified day ranges; (3) did not violate
the protocol in ways that could affect the evaluation of immunoge-
nicity; and (4) consented to immunogenicity follow-up and provided
a serum sample for immunogenicity analysis during the LTFU period.
Fig. 1. Participant disposition. LTFU=long-term follow-up. qHPV=quadrivalent human
papillomavirus. *Nordic participants who received placebo in the base study are not
included in this report.
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and 18 was assessed by computing: (1) point estimates of GMTs and
corresponding 95% confidence intervals (CI); and (2) point estimates
of seropositivity percentages and corresponding 95% CI, based on
both the cLIA and the IgG-LIA.
2.6. Role of the funding source
In close collaboration with the external investigators, employees
of Merck Sharpe & Dohme, a subsidiary of Merck & Co., Inc., Kenil-
worth, NJ, USA, the sponsor and funder of the study, were directly
involved in the design and conduct of the study; collection, manage-
ment, analysis, and interpretation of the data; and the preparation
and review of the manuscript. Each author had access to all study
results, critically contributed to manuscript development, and
approved the final version of the paper. The presentation also under-
went formal review by the sponsor. The decision to submit the manu-
script for publication was made by the corresponding author in
conjunction with the sponsor and co-authors. The sponsor did not
have the potential to prevent submission of the manuscript. The
opinions expressed in the manuscript represent the collective views
of the authors and do not necessarily reflect the official position of
the sponsor.
3. Results
Participants were enrolled in the FUTURE II base study beginning
in June 2002. The base study included 5493 women from Denmark,
Iceland, Norway, and Sweden who were vaccinated with either qHPV
vaccine or placebo, including 2750 women who received at least one
dose of qHPV vaccine during the base-study vaccination phase
(Fig. 1). Of these, 2650 participants consented to be included in regis-
try searches for effectiveness information, and 2385 consented to
provide serum samples for immunogenicity analyses (supplementary
Table 1). Numbers of participants contributing to the primary and
secondary effectiveness analyses are presented in supplementary
Table 2. The data cut-off date for registry analyses in the LTFU exten-
sion was March 1, 2017; the last participant visit for blood collection
was March 31, 2017.
At enrollment in the base study, the median age of the LTFU-study
participants who received qHPV vaccine at the start of the base study
was 21 years (range: 1623 years; supplementary Table 3). The
majority of participants were from Denmark and Norway (40¢8% and
30¢9%, respectively).
For the primary effectiveness analysis, the PPE population
involved 2121 participants contributing a total follow-up of 24,099¢0
person-years since month 7 of the base study (ie, one month after the
last qHPV vaccine dose administration). PPE analyses are based on a
maximum follow-up of 14¢0 years (median 11¢9 years) post-vaccine
Dose 3, or 14¢4 years (median 12¢4 years) post-vaccine Dose 1. Over-
all, 96¢9% of participants had at least one cervical cytology screening
during the LTFU period; the proportion by country was: Denmark,
97¢4%; Iceland, 97¢1%; Norway, 97¢6%; and Sweden, 94¢2%.
Under the hypothesis of vaccine effectiveness 90%, the antici-
pated incidence rate of HPV16/18-related CIN2 or worse in the PPE
population should not exceed 0¢0287/100 person-years. Based on the
24,099¢0 person-years of follow-up time accrued through the end of
the LTFU study, 7 cases of HPV16/18-related CIN2 or worse were
expected if vaccine effectiveness was maintained at 90%. However,
in the actual study, there were no cases of HPV16/18-related CIN2 or
worse in the PPE population at any time during the base study or
LTFU, indicating a vaccine effectiveness of 100% (95% CI 94¢7100)
(table 1). Given the number of eligible participants for this analysis, a
minimum of 2634 person-years of follow-up time is necessary in any
given time interval since year 4 to draw firm conclusions from the
results of this analysis based on the statistical method (see appendix).A total of 3197¢6 person-years have accrued over the period from 10
to 12 years following vaccination, which is sufficient time to conclude
that the qHPV vaccine continued to be effective through 12 years
(table 1). The same pattern was seen in the interval up to 14 years,
indicating a trend of continued effectiveness through 14 years. How-
ever, there is insufficient follow-up time in the 12 to 14 years interval
to make a conclusive claim of effectiveness beyond 12 years.
Fig. 2 shows the control chart monitoring of observed vaccine
effectiveness. Shaded time intervals represent time periods for which
the follow-up time is insufficient for attributing statistical signifi-
cance to the plotted incidences crossing or not crossing the 2- or 3-
sigma limits. None of the points on the graph, which represent the
number of cases observed during each 2-year interval, crossed the 2-
or 3-sigma control limits during the evaluable time intervals
(unshaded intervals in Fig. 2). Neither of the two criteria pre-specified
as indicative of waning vaccine effectiveness were met. Thus, there
was no evidence of decreased vaccine effectiveness in the PPE popu-
lation through at least 12 years after the first vaccine dose.
Pre-specified supportive analyses were conducted in the HNRT
population, which comprised susceptible participants and did not
exclude protocol violators. Based on the 27,395¢3 person-years of fol-
low-up time accrued in the LTFU study, 8 cases of HPV16/18-related
CIN2 or worse were expected if vaccine effectiveness was maintained
at 90%. There was one case of HPV16/18-related CIN2 or worse in
this population throughout the base and LTFU study (table 1), indicat-
ing a vaccine effectiveness of 98¢7% (95% CI 92¢9100). The single
participant with a case of the primary endpoint had positive PCR
results at month 7 for HPV16 (suggesting early infection occurring
before full vaccination) and was diagnosed with a CIN3 lesion which
Table 1
Analysis of qHPV vaccine effectiveness against HPV16/18-related CIN2 or worse by time since qHPV vaccination, HPV type,
and lesion type








HPV16/18-related CIN2 or worse 0/2121 24099¢0 0¢0 (0¢0<0¢1) 100 (94¢7100¢0)
By time since qHPV vaccine Dose 1
4 years 0/2121 7246¢8 0¢0 (0¢00¢1)
>4 to 6 years 0/2121 4220¢4 0¢0 (0¢00¢1)
>6 to 8 years 0/2089 4121¢8 0¢0 (0¢00¢1)
>8 to 10 years 0/2022 3901¢0 0¢0 (0¢00¢1)
>10 to 12 years 0/1855 3197¢6 0¢0 (0¢00¢1)
>12 to 14 years 0/1211 1393¢4 0¢0 (0¢00¢3)
>14 to 16 years 0/122 18¢0 0¢0 (0¢020¢5)
By HPV type
HPV16-related 0/1814 20583¢9 0¢0 (0¢0<0¢1)
HPV18-related 0/2018 22940¢6 0¢0 (0¢0<0¢1)
By lesion type
CIN2 0/2121 24099¢0 0¢0 (0¢0<0¢1)
CIN3 0/2121 24099¢0 0¢0 (0¢0<0¢1)
AIS 0/2121 24099¢0 0¢0 (0¢0<0¢1)
Cervical cancer 0/2121 24099¢0 0¢0 (0¢0<0¢1)
HNRT population
z
HPV16/18-related CIN2 or worse 1/2292 27395¢3 <0¢1 (<0¢1<0¢1) 98¢7 (92¢9100)
By time since qHPV vaccine Dose 1
4 years 0/2292 9168¢0 0¢0 (0¢0<0¢1)
>4 to 6 years 0/2292 4558¢4 0¢0 (0¢00¢1)
>6 to 8 years 0/2254 4452¢2 0¢0 (0¢00¢1)
>8 to 10 years 1/2186 4223¢6 <0¢1 (<0¢10¢1)
>10 to 12 years 0/2013 3465¢0 0¢0 (0¢00¢1)
>12 to 14 years 0/1303 1509¢5 0¢0 (0¢00¢2)
>14 to 16 years 0/127 18¢6 0¢0 (0¢019¢9)
By HPV type
HPV16-related 1/1978 23624¢9 <0¢1 (<0¢1<0¢1)
HPV18-related 0/2189 26166¢0 0¢0 (0¢0<0¢1)
By lesion type
CIN2 0/2292 27395¢3 0¢0 (0¢0<0¢1)
CIN3 1/2292 27395¢3 <0¢1 (<0¢1<0¢1)
AIS 0/2292 27395¢3 0¢0 (0¢0<0¢1)
Cervical cancer 0/2292 27395¢3 0¢0 (0¢0<0¢1)
AIS=adenocarcinoma in situ. CI=confidence interval. CIN=cervical intraepithelial neoplasia. HNRT= HPV-naïve to relevant
type. HPV=human papillomavirus. N=number of participants who received at least one dose of the qHPV vaccine at the start
of the base study and consented to effectiveness follow-up. n=number of participants who had at least one follow-up visit.
PPE=per-protocol effectiveness. qHPV=quadrivalent human papillomavirus.
* Vaccine effectiveness measures the relative reduction of the disease incidence in vaccine recipients compared with the
baseline incidence rate of 0¢287/100 person-years established from the incidence rate in an unvaccinated cohort.
y Person-years’ follow-up for the PPE population was calculated starting from month 7 of the base study, the case count-
ing start time in the PPE population.
z Person-years’ follow-up for the HNRT population was calculated starting from day 1 of the base study, the case count-
ing start time in the HNRT population.
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the LTFU study (see appendix for details). Similar to the PPE popula-
tion, this analysis showed that the qHPV vaccine continued to be
effective through 12 years, with a trend of continued effectiveness up
to 14 years. Based on the control chart analysis, significant vaccine
effectiveness was demonstrated through 12 years post-vaccine
Dose 1 (Fig. 2).
There was one case of the secondary endpoint of HPV6/11/16/18-
related CIN of any grade, AIS, cervical cancer, vulvar cancer, and vagi-
nal cancer (HPV16-related CIN1) in the PPE population during
26,513¢3 total person-years of follow-up (table 2). The single PPE-eli-
gible participant who developed this endpoint had positive PCR
results for HPV45 and 51 at baseline and was diagnosed with a CIN1
lesion which was positive for HPV16, 45, and 52 during the 68-year
follow-up interval in the LTFU study; HPV16 was detected only at the
time of the CIN1 diagnosis, and was therefore unlikely to have caused
the lesion (see appendix for details). There were no HPV6/11/16/18-
related cases of vulvar or vaginal cancer in the PPE population.
There were 47 cases of CIN2 or worse related to 10 non-qHPV
vaccine types (31/33/35/39/45/51/52/56/58/59) in the HNRTpopulation over 28,032¢2 person-years’ follow-up, representing
an incidence of 0¢2 (95% CI 0¢10¢2)/100 person-years at risk
(supplementary Table 4). Assuming that an estimated 36% of
cases of CIN2 or worse were caused by these 10 non-vaccine
types, the expected incidence in a non-vaccinated population
would be 0¢187/100 person-years. Based on the person-years at
risk for the HNRT population, approximately 52 cases of CIN2 or
worse related to the non-vaccine types would be expected. The
observation that non-vaccine HPV type-related isease cases
continued to accrue over the study duration suggests that the
population continued to be exposed to these HPV types during
the study.
An exploratory analysis of vaccine effectiveness was conducted in
women with serologic evidence of prior HPV infection (ie, positive by
serology), but without active infection as assessed by negative PCR
on day 1 of the base study. No cases of HPV6/11/16/18-related CIN,
vulvar, or vaginal cancer were observed in this population over
4064¢6 person-years of follow-up (supplementary Table 5). While the
sample size was limited (n = 337) and the study was not powered to
assess effectiveness in this subgroup, this finding suggests that HPV
Table 2
Incidence of HPV6/11/16/18-related CIN (any grade), AIS, cervical cancer, vulvar cancer, and vaginal
cancer by time since qHPV vaccination, HPV type, and lesion type






HPV6/11/16/18-related CIN (any grade),
AIS, cervical cancer, vulvar cancer, and
vaginal cancer
1/2312 26513¢3 <0¢1 (<0¢1<0¢1)
By time since qHPV vaccine Dose 1
4 years 0/2312 7899¢3 0¢0 (0¢0<0¢1)
>4 to 6 years 0/2312 4610¢0 0¢0 (0¢00¢1)
>6 to 8 years 1/2286 4519¢7 <0¢1 (<0¢10¢1)
>8 to 10 years 0/2228 4306¢7 0¢0 (0¢00¢1)
>10 to 12 years 0/2054 3565¢4 0¢0 (0¢00¢1)
>12 to 14 years 0/1367 1591¢8 0¢0 (0¢00¢2)
>14 to 16 years 0/143 20¢3 0¢0 (0¢018¢1)
By HPV type
HPV6-related 0/2005 23002¢7 0¢0 (0¢0<0¢1)
HPV11-related 0/2005 23002¢7 0¢0 (0¢0<0¢1)
HPV16-related 1/1903 21769¢1 <0¢1 (<0¢1<0¢1)
HPV18-related 0/2148 24656¢8 0¢0 (0¢0<0¢1)
By lesion type
CIN1 1/2164 24571¢9 <0¢1 (<0¢1<0¢1)
CIN2 or worse 0/2164 24571¢9 0¢0 (0¢0<0¢1)
CIN2 0/2,164 24571¢9 0¢0 (0¢0<0¢1)
CIN3 or worse 0/2,164 24571¢9 0¢0 (0¢0<0¢1)
CIN3 0/2,164 24571¢9 0¢0 (0¢0<0¢1)
AIS 0/2,164 24571¢9 0¢0 (0¢0<0¢1)
Cervical cancer 0/2,164 24571¢9 0¢0 (0¢0<0¢1)
Vulvar cancer 0/2,312 26509¢0 0¢0 (0¢0<0¢1)
Vaginal cancer 0/2,312 26509¢0 0¢0 (0¢0<0¢1)
HNRT population
y
HPV6/11/16/18-related CIN (any grade),
AIS, cervical cancer, vulvar cancer, and
vaginal cancer
2/2488 29984¢4 <0¢1 (<0¢1<0¢1)
By time since qHPV vaccine Dose 1
4 years 0/2488 9952¢0 0¢0 (0¢0<0¢1)
>4 to 6 years 0/2488 4959¢7 0¢0 (0¢00¢1)
>6 to 8 years 1/2457 4862¢1 <0¢1 (<0¢10¢1)
>8 to 10 years 1/2397 4640¢5 <0¢1 (<0¢10¢1)
>10 to 12 years 0/2218 3843¢6 0¢0 (0¢00¢1)
>12 to 14 years 0/1461 1706¢3 0¢0 (0¢00¢2)
>14 to 16 years 0/146 20¢2 0¢0 (0¢018¢3)
By HPV type
HPV6-related 0/2177 26252¢2 0¢0 (0¢0<0¢1)
HPV11-related 0/2177 26252¢2 0¢0 (0¢0<0¢1)
HPV16-related 2/2074 24961¢1 <0¢1 (<0¢1<0¢1)
HPV18-related 0/2328 28078¢6 0¢0 (0¢0<0¢1)
By lesion type
CIN1 1/2328 27805¢2 <0¢1 (<0¢1<0¢1)
CIN2 or worse 1/2328 27805¢1 <0¢1 (<0¢1<0¢1)
CIN2 0/2328 27805¢2 0¢0 (0¢0<0¢1)
CIN3 or worse 1/2328 27805¢1 <0¢1 (<0¢1<0¢1)
CIN3 1/2328 27805¢1 <0¢1 (<0¢1<0¢1)
AIS 0/2328 27805¢2 0¢0 (0¢0<0¢1)
Cervical cancer 0/2328 27805¢2 0¢0 (0¢0<0¢1)
Vulvar cancer 0/2487 29976¢6 0¢0 (0¢0<0¢1)
Vaginal cancer 0/2487 29976¢6 0¢0 (0¢0<0¢1)
AIS=adenocarcinoma in situ. CI=confidence interval. CIN=cervical intraepithelial neoplasia.
HPV=human papillomavirus. HNRT=HPV-naïve to relevant type. N=number of participants who
received at least one dose of the qHPV vaccine at the start of the base study and consented to effec-
tiveness follow-up. n=number of participants who had at least one follow-up visit, PPE=per-protocol
effectiveness. qHPV=quadrivalent human papillomavirus.
* Person-years’ follow-up was calculated starting from month 7 of the base study, the case
counting start time in the PPE population.
y Person-years’ follow-up was calculated starting from day 1 of the base study, the case counting
start time in the HNRT population.
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serologic evidence of a prior infection.
Anti-HPV6/11/16/18 cLIA GMTs were highest at month 7, declined
most sharply between months 7 and 24, and were generally stable
between month 24 through month 168 (table 3; supplementary
figure 1).After 14 years of follow-up (month 168), >90% of participants in
the PPI population remained seropositive for HPV types 6, 11, and 16
and 52¢4% of participants remained seropositive for HPV18 based on
the cLIA (table 3). The decrease in seropositivity for HPV18 as
assessed by cLIA cannot be interpreted as decrease in protection. In
analyses using the more sensitive IgG-LIA, >90% of participants
Fig. 2. Control chart analysis of effectiveness of qHPV vaccine against HPV16/18-related CIN2 or worse in the PPE population (A) and HNRT population (B). Shaded areas are inter-
vals with insufficient follow-up time to declare statistical significance. CIN=cervical intraepithelial neoplasia. HNRT=HPV-naïve to relevant type. HPV=human papillomavirus.
PPE=per-protocol effectiveness. qHPV=quadrivalent human papillomavirus.
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month 168 (table 3). Moreover, if being seronegative by cLIA for
HPV18 would indicate being susceptible to HPV18-related infection
and disease, at least 33% of participants in the LTFU study would be
susceptible (since the seropositivity rate at Month 48, before the start
of the LTFU study, was 67%). Considering that the incidence of
HPV16/18-related CIN2 or worse in an unvaccinated Nordic popula-
tion is estimated as 0¢287/100 person-years, 80% and 20% of such
lesions are estimated to be caused by HPV16 and HPV18, respectively
(based on results of the efficacy studies of the qHPV vaccine) [13,14].
There were 17,526.6 person-years at risk in PPE analyses during the
LTFU study for the primary endpoint of HPV16/18-related CIN2 or
worse (supplementary Table 6); 33% of participants being susceptible
to HPV18-related infection and disease would result in three to four
cases of HPV18-related CIN2 or worse during the LTFU study. As seen
in Table 1, no case was observed.
4. Discussion
The qHPV vaccine demonstrated 100% effectiveness against
HPV16/18-related CIN2 or worse in the PPE population through
12 years after the first vaccine dose, with a continuing trend of effec-
tiveness observed through 14 years. Continued effectiveness was
observed when evaluating the secondary endpoint of combined inci-
dence of HPV6/11/16/18-related CIN (any grade), AIS, cervical, vulvar,
and vaginal cancer as well. In supportive analyses conducted in the
HNRT population, there was one case of HPV16-related CIN3. Further
examination of the course of events for this case indicated that the
participant may have been infected with HPV16 prior to completion
of the vaccine series in the base study, preceding development of the
CIN3 lesion 810 years later during the LTFU period. This caseunderlines the fact that the vaccine is prophylactic and does not have
therapeutic efficacy.
Sustained antibody responses to the vaccine HPV types were
observed through 14 years post-vaccination. While the seropositivity
rates remained high (>90%) for HPV types 6, 11, and 16 through year
14 post-vaccination using both the cLIA and IgG-LIA, the proportion
of participants who were seropositive for HPV18 by cLIA declined to
52¢4% at 14 years post-vaccination. However, when the same serum
samples were tested using the IgG-LIA, a more sensitive assay that
measures all IgG antibodies produced in response to vaccination,
>90% of participants were seropositive for HPV18 at this timepoint.
While the minimum antibody titres necessary for protection are
unknown, results from animal studies suggest very low titres (up to
100-fold lower than the threshold of detection of a standard pseudo-
virion-based neutralization assay) may be protective [34]. As there
were no observed cases of HPV18-related CIN2 or worse among
women vaccinated with qHPV in this study, results suggest protective
efficacy via immune memory or lower than cLIA-detectible HPV18
antibody levels. Therefore, the low seropositivity rate observed for
HPV18 by cLIA appears to be of limited clinical significance.
The antibody levels assessed by cLIA and IgG-LIA are expressed in
mMU/mL, which is consistent with the previous published literature
and global regulatory documents. World Health Organization inter-
national antibody units (IU) have only been established for HPV16
and HPV18, but are not available for other HPV types. A conversion
factor from mMU/mL in cLIA and IgG-LIA to IU/mL has been proposed
in a previous publication [35].
The study had a unique design: while the LTFU study was an
extension of a randomized, placebo-controlled Phase 3 study
(FUTURE II), the LTFU study in Nordic participants incorporated ele-
ments of a population-based epidemiological study with minimal
Table 3
Summary of cLIA and IgG-LIA GMTs and seropositivity through month 168 in the PPI population
Young women 1623 years of age (N=2750)
cLIA Time since Dose 1 n cLIA GMT
(95% CI), mMu/mL
cLIA seropositivity* (95% CI)z, %
Anti-HPV6 Day 1 1380 <8 (<8, <8) 0¢0 (0¢0, 0¢3)
Month 7 272 521¢5 (473¢8, 574¢0) 99¢6 (98¢0, 100)
Month 24 280 133¢4 (119¢5, 149¢0) 97¢9 (95¢4, 99¢2)
Month 48 1253 97¢8 (92¢7, 103¢2) 94¢1 (92¢6, 95¢3)
Month 108 1234 89¢2 (84¢7, 94¢0) 94¢4 (93¢0, 95¢6)
Month 168 1058 78¢4 (73¢8, 83¢2) 90¢6 (88¢7, 92¢3)
Anti-HPV11 Day 1 1380 <8 (<8, <8) 0¢0 (0¢0, 0¢3)
Month 7 273 738¢8 (665¢4, 820¢4) 99¢6 (98¢0, 100)
Month 24 280 174¢2 (157¢0, 193¢2) 98¢6 (96¢4, 99¢6)
Month 48 1253 123¢5 (117¢2, 130¢1) 97¢4 (96¢4, 98¢2)
Month 108 1234 85¢2 (80¢7, 90¢0) 95¢5 (94¢1, 96¢6)
Month 168 1058 66¢8 (62¢6, 71¢3) 91¢1 (89¢2, 92¢8)
Anti-HPV16 Day 1 1319 <12 (<12, <12) 0¢0 (0¢0, 0¢3)
Month 7 263 2233¢8 (1917¢7, 2602¢0) 100 (98¢6, 100)
Month 24 271 546¢9 (486¢5, 614¢7) 98¢9 (96¢8, 99¢8)
Month 48 1194 493¢4 (464¢8, 523¢7) 98¢9 (98¢1, 99¢4)
Month 108 1179 348¢6 (328¢3, 370¢2) 99¢1 (98¢3, 99¢5)
Month 168 1005 291¢2 (272¢1, 311¢5) 98¢3 (97¢3, 99¢0)
Anti-HPV18 Day 1 1483 <8 (<8, <8) 0¢0 (0¢0, 0¢2)
Month 7 297 433¢7 (383¢1, 491¢0) 98¢3 (96¢1, 99¢5)
Month 24 306 59¢8 (51¢0, 70¢2) 74¢5 (69¢2, 79¢3)
Month 48 1343 43¢8 (40¢5, 47¢4) 67¢0 (64¢4, 69¢5)
Month 108 1332 32¢5 (30¢2, 34¢9) 59¢9 (57¢2, 62¢6)
Month 168 1131 26¢1 (24¢1, 28¢2) 52¢4 (49¢5, 55¢4)
Young women 1623 years of age (N=2750)
IgG-LIA Time since Dose 1 n IgG-LIA GMT
(95% CI), mMu/mL
IgG-LIA Seropositivityy (95% CI)z, %
Anti-HPV6 Month 108 1235 95¢2 (90¢5, 100¢1) 97¢6 (96¢6, 98¢4)
Month 168 1054 81¢2 (76¢1, 86¢5) 98¢1 (97¢1, 98¢8)
Anti-HPV11 Month 108 1235 67¢4 (64¢3, 70¢8) 96¢3 (95¢1, 97¢3)
Month 168 1055 53¢5 (50¢2, 57¢0) 98¢0 (97¢0, 98¢8)
Anti-HPV16 Month 108 1181 346¢1 (327¢3, 365¢9) 100 (99¢7, 100)
Month 168 1000 290¢2 (271¢0, 310¢8) 100 (99¢6, 100)
Anti-HPV18 Month 108 1333 46¢1 (43¢3, 49¢2) 91¢4 (89¢7, 92¢8)
Month 168 1036 36¢5 (33¢7, 39¢5) 93¢8 (92¢2, 95¢2)
CI=confidence interval. cLIA=competitive Luminex immunoassay. GMT=geometric mean titre. HPV=human
papillomavirus. IgG-LIA=immunoglobulin G Luminex immunoassay. mMU=milli Merck units. N=number of
participants who have received at least one dose of the qHPV vaccine at the start of the base study. n=number
of participants contributing to the analysis. PPI=per-protocol immunogenicity.
* The serostatus cut-offs for anti-HPV6, 11, 16, and 18 serum cLIAwere 20, 16, 20, and 24mMU/mL, respectively.
y Percent represents proportion of participants with IgG-LIA anti-HPV serum levels 15, 15, 7, and
10 mMU/mL for HPV types 6, 11, 16, and 18, respectively, for month 108. For month 168, anti-HPV serum lev-
els 9, 6, 5, and 5 mMU/mL for HPV types 6, 11, 16, and 18, respectively, were used as cut-off values. The origi-
nal version of the IgG LIA was used for testing month 108 samples. A new version of the IgG LIA was used for
testing month 168 samples. The newer version of the assay was bridged to the earlier version to ensure com-
parable antibody measurements between the two versions.
z The CIs are computed based on exact methods.
8 S.K. Kjaer et al. / EClinicalMedicine 23 (2020) 100401loss to follow-up (ie, passive and comprehensive surveillance based
on health registry data; endpoints based on standard clinical prac-
tice; possibility to estimate expected incidence of endpoints among
non-vaccinated women with the initial same level of sexual activity).
Cervical cancer screening is widely implemented in national pro-
grams in Nordic countries, and records are available in virtually com-
plete nationwide registries. As anticipated, retention rates in the
LTFU study were high with favorable adherence (ie, 97¢1% of the par-
ticipants who consented for effectiveness follow-up had at least one
cervical cytology screening during the LTFU period), supporting the
robustness of the analyses presented. The same rigorous methodol-
ogy (eg, pathological diagnosis adjudication; PCR testing for HPV
DNA) as in the base study was also used to assess outcomes in the
LTFU study, ensuring consistency throughout the 14 years of total fol-
low-up and a continuous level of rigor.
The participants in this cohort represent a sentinel cohort
with an observed follow-up time of approximately 5 years morethan the first cohort which received qHPV vaccine post-licensure.
This provides sufficient lead time for identifying vaccine break-
through cases. Threshold levels for incidence of breakthrough
cases were established to define a point where vaccine effective-
ness may have waned by a moderate amount, and where there
may exist a need for a booster vaccine dose. This was evaluated
using control chart methods, an innovative aspect of this study,
which had the advantage of monitoring disease incidence in real
time during the LTFU study. This real-time monitoring is condu-
cive to prompt detection of a decrease in vaccine effectiveness,
should any such decline occur [36]. As no waning of immunity
was observed in this cohort since the first vaccine dose, imple-
mentation of booster vaccination in this population is not war-
ranted. Also, as the study participants were vaccinated in the
base study at 16 to 23 years of age, they reached approximately
30 to 37 years of age by the end of the LTFU study after 14 years
of total follow-up. This covers the age range for peak incidence of
S.K. Kjaer et al. / EClinicalMedicine 23 (2020) 100401 9HPV16/18-related CIN2/3, as well as the beginning of the period
of highest cervical cancer risk [37].
The accrual of non-vaccine HPV type-related disease during the
LTFU study is consistent with previous observations that the qHPV
vaccine provides only limited cross-protection against non-vaccine
HPV types (ie, partial protection against HPV31-related infection and
disease) [38,39]. In addition, these data highlight that the women
included in the cohort remained sexually active and continued to
acquire cervical dysplasia as they approached mid-adulthood during
the study.
Limitations of this study include the lack of a control arm in the
LTFU study, as participants who received placebo in the base study
were offered the intervention, ie, qHPV vaccination upon base-study
completion for ethical reasons and to be in compliance with the Hel-
sinki declaration of clinical trial conduct. Therefore, effectiveness was
determined relative to estimated incidence in an unvaccinated popu-
lation. In fact, the strong adherence to routine cervical screening pro-
grams in Nordic countries, the ability to compare cervical disease
incidence rates in the study population, together with the robustness
of the statistical methods and analyses used in the study, supported
the design and conduct of a hypothesis-driven LTFU study and
allowed rigorous conclusions to be drawn. Because the effectiveness
assessment in the LTFU was based on passive surveillance of routine
clinical practice, endpoints were limited to HPV-related cervical pre-
cancers and cancers and vulvar and vaginal cancers, as diagnoses of
other HPV-related disease endpoints (eg, vulvar/vaginal/anal intrae-
pithelial neoplasia) assessed during the base study would not have
been systematically collected in registry data in all the Nordic coun-
tries. Given that the natural history, pathophysiology, and mecha-
nisms of protection elicited by HPV vaccination are similar at
different anatomic sites, it is reasonable to assume that results for
cervical endpoints would be applicable to other HPV-related disease
endpoints.
In summary, the study results demonstrate significant qHPV vac-
cine effectiveness of 100% through 12 years after the first dose of
qHPV vaccine, with a continuing trend of protection up to 14 years
post-vaccination in the population of Nordic women. There was no
evidence of waning immunity over this time period, suggesting that
there is no need for a booster dose. Thus, the effectiveness results
were consistent with prolonged and sustained immunity against the
vaccine-related HPV types. A 9-valent HPV (9vHPV) vaccine has been
developed and licensed in 2014 to protect against infection and dis-
ease caused by the four HPV types covered by the qHPV vaccination
and the five HPV types which are most commonly associated with
cervical cancer after HPV16 and 18 [9]. Based on epidemiological
studies, the 9vHPV vaccine has the potential to prevent approxi-
mately 90% cervical cancer cases, 7085% high-grade cervical dyspla-
sia, 8595% of HPV-related vulvar, vaginal, and anal cancers, and 90%
of genital warts [9]. The long-term effectiveness that was demon-
strated for the qHPV vaccine is likely to be applicable to the 9vHPV
vaccine since the two vaccines are manufactured similarly, share
antigens for four HPV types, and have similar efficacy and immunoge-
nicity profiles for HPV6, 11, 16, and 18 [9]. A long-term effectiveness
study of the 9vHPV vaccine is ongoing in Nordic countries to confirm
this expectation [36].
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